Skip to main content
ALTERITY THERAPEUTICS LIMITED logo

ALTERITY THERAPEUTICS LIMITED - Investor Relations & Filings

Listed
Ticker · ATH ISIN · AU0000043945 LEI · 52990045JUZVZ9QL3159 ASX Professional, scientific and technical activities
Open in API
Filings indexed 2,366 across all filing types
Latest filing 2026-07-07 Regulatory Filings
Country AU Australia
Listing ASX ATH · 12 venues

About ALTERITY THERAPEUTICS LIMITED

https://alteritytx.com/

Alterity Therapeutics Limited is a clinical-stage company focused on developing disease-modifying therapies for neurodegenerative disorders. The company's research and development efforts center on addressing the underlying pathology of conditions such as Multiple System Atrophy (MSA) and Parkinson's disease. Its lead therapeutic candidate, ATH434, is an orally administered small molecule designed to redistribute excess iron in the brain, thereby inhibiting the aggregation of alpha-synuclein and reducing oxidative stress. By targeting these specific mechanisms, the company aims to preserve neuronal integrity and slow the progression of parkinsonian diseases. Alterity utilizes a specialized platform to identify compounds that modulate metal-protein interactions, focusing on first-in-class treatments for orphan diseases with high unmet medical needs.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer. It is a short document (1505 characters) that serves as a cover for an exhibit (99.1) regarding FDA meeting minutes. It does not contain substantive financial statements or performance data, nor does it fit into specific categories like earnings releases or management reports. Per the rules, Form 6-K filings that act as general regulatory announcements or cover letters for exhibits without providing the primary financial report itself are classified as Regulatory Filings (RNS).
2026-07-07 English
FDA Meeting Minutes Confirm Registrational Path for ATH434 4 pages 722.8KB
Regulatory Filings Classification · 95% confidence The document is a press release issued by Alterity Therapeutics announcing the receipt of official FDA meeting minutes regarding the registrational pathway for their drug candidate, ATH434. It provides a summary of the regulatory feedback and the company's forward-looking clinical development strategy. It does not contain audited financial statements, nor is it a formal regulatory filing itself, but rather a corporate announcement regarding regulatory progress. As it does not fit into specific categories like Earnings Release (no financial results) or Legal Proceedings (it is a regulatory update), it falls under the general Regulatory Filings (RNS) category as a corporate announcement.
2026-07-07 English
Application for quotation of securities - ATH 8 pages 20.7KB
Share Issue/Capital Change Classification · 100% confidence The document is an 'Appendix 2A' filing from the Australian Securities Exchange (ASX), which is a standard regulatory form used by companies to apply for the quotation of new securities resulting from the exercise of options or conversion of convertible securities. This falls under the category of share issuance and capital changes. Since it specifically details the issuance of new shares following the exercise of options, it is classified as a Share Issue/Capital Change (SHA).
2026-07-01 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer submitted under the Securities Exchange Act of 1934. It indicates filing under Form 20-F or 40-F annually and includes signature authorization. The length is short (1492 characters) and contains a reference to an application for quotation of securities and a signature block. This document is not a full financial report like an Annual Report (10-K) or Interim Report (IR). Given the short length and that it is a report submission under SEC rules for foreign issuers, it aligns with Regulatory Filings (RNS) which is a fallback category for miscellaneous filings that do not clearly fit other categories.
2026-07-01 English
FORM 6-K
Major Shareholding Notification Classification · 95% confidence The document is titled 'FORM 6-K' which is a type of report submitted by foreign private issuers to the SEC pursuant to rules under the Securities Exchange Act of 1934. It is not an annual or interim financial report, audit report, earnings release, or management report. It includes a mention of an exhibit for 'Change in substantial holding', indicating updated shareholding information. The length is short and form 6-K filings generally report regulatory or material information updates but not full financial reports. The primary content is shareholding change information, so the most appropriate classification is 'Major Shareholding Notification' (MRQ).
2026-06-30 English
Change in substantial holding 6 pages 349.5KB
Major Shareholding Notification Classification · 100% confidence The document is a 'Form 604: Notice of change of interests of substantial holder' filed under the Australian Corporations Act 2001, Section 671B. This form is used to notify the market when a shareholder's interest in a company crosses a substantial threshold (typically 5%). This falls under the category of Major Shareholding Notification.
2026-06-30 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.